Education
About Us
Working with TipRanks
Follow Us
Pacira (PCRX)
:PCRX
PCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.16 - $31.67
Previous CloseN/A
Volume54.84K
Average Volume (3M)1.00M
Market Cap
$1.20B
Enterprise Value$1.08B
Total Cash (Recent Filing)$26.13M
Total Debt (Recent Filing)$25.05M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Apr 30, 2025EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding46,276,240
10 Day Avg. Volume961,183
30 Day Avg. Volume1,000,919
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.59
Price to Cash Flow (P/CF)8.40
P/FCF Ratio8.20
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda51.17
Forecast
1Y Price Target
$34.29Price Target Upside31.88% Upside
Rating ConsensusHold
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Patent SettlementThe settlement with Fresenius Kabi and Jiangsu Hengrui is seen as favorable for Pacira, representing profound upside to the current valuation.
Revenue GrowthRevenue growth is expected to accelerate with NOPAIN driving higher volumes, and the settlement is seen as key to unlocking a re-rate in the stock's valuation multiple.
Strategic DirectionManagement's 5-year plan to build an innovative pipeline, including PCRX-201 knee OA gene therapy, adds upside potential to Pacira's growth story.
Bears Say
Competitive PressuresThere are concerns about competitive pressures impacting Pacira's market share.
Regulatory ChallengesRegulatory challenges could pose risks to Pacira's upcoming product launches.
---
Ownership Overview
2.79% Insiders
22.32% Mutual Funds
1.95% Other Institutional Investors
41.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $11.16 and its highest was $31.67 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $1.20B.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Apr 30, 2025 which is in 5 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Feb 27, 2025. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.835 by $0.075.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.6.
How many shares outstanding does Pacira have?
Pacira has 46,276,240 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.91 in its last earnings report, beating expectations of $0.835. Following the earnings report the stock price went down -5.24%.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
---
Pacira Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$34.29 (31.88% Upside)
$34.29 (31.88% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 135.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 13.0%
Last 30 Days ▼ 13.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.38%
12-Months-Change
Fundamentals
Return on Equity
-12.08%
Trailing 12-Months
Asset Growth
-1.33%
Trailing 12-Months
Company Description
Pacira
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
---
PCRX Company Deck
---
PCRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Pacira BioSciences reported strong financial performance for 2024 with record revenues and significant reimbursement progress for its flagship product, EXPAREL. However, the delayed uptake of the No Pain Act reimbursement and increased operating expenses are challenges that the company needs to navigate. The strategic acquisition of GQ Bio and expansion of commercial coverage are notable steps forward.Read More>---
PCRX Stock 12 Month Forecast
Average Price Target
$34.29
▲(31.88% Upside)
Technical Analysis
Opko Health
―
Innoviva
―
Iovance Biotherapeutics
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
15/41 ratings generated profit
1 Year Average Return
-3.67%
reiterated a buy rating 18 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 36.59% of your transactions generating a profit, with an average return of -3.67% per trade.
---